Crinetics Pharmaceuticals, Inc.
CRNX
Rangering i aksjer
#2240
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Aksjekurs
$84.95
Sist synkronisert: 2026-09-01
Markedsverdi
$9.00B
Endring (1 dag)
0.00%
Endring (1 år)
98.25%
Land
US
Handel Crinetics Pharmaceuticals, Inc. (CRNX)
Kategori
Healthcare
P/S-forhold for Crinetics Pharmaceuticals, Inc. (CRNX)
P/S-forhold per October 2026 TTM: 213.80
Ifølge Crinetics Pharmaceuticals, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 213.80. Ved slutten av 2023 hadde selskapet et P/S-forhold på 514.87.
P/S-historikk for Crinetics Pharmaceuticals, Inc. fra 2016 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 213.80 | -94.62% |
| 2024 | 3.98K | 672.12% |
| 2023 | 514.87 | 156.39% |
| 2022 | 200.82 | -80.18% |
| 2021 | 1.01K | -83.26% |
| 2020 | 6.05K | 1,090.15% |
| 2019 | 508.42 | 239.01% |
| 2018 | 149.97 | -9.84% |
| 2017 | 166.33 | -71.20% |
| 2016 | 577.51 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 10.02 | -95.31% |
US
|
|
| 40.55 | -81.03% |
US
|
|
| 3.96 | -98.15% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -95.25% |
NL
|
